Leveraging model-informed approaches for drug discovery and development in the cardiovascular space

• Published in: Journal of pharmacokinetics and pharmacodynamics Vol. 45; no. 3; pp. 355 - 364
• Main Authors: Dockendorf, Marissa F., Vargo, Ryan C., Gheyas, Ferdous, Chain, Anne S. Y., Chatterjee, Manash S., Wenning, Larissa A.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2018; Springer Nature B.V
• Subjects: Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Clinical trials; Computer simulation; Decision making; Drug development; Drug discovery; Global health; Health risks; Pharmacology/Toxicology; Pharmacy; Prolongation; Review Paper; Simulation; Veterinary Medicine/Veterinary Science; Clinical trial simulation; Drug development; Cardiovascular; Exposure–response; Pharmacokinetic/pharmacodynamic modeling
• ISSN: 1567-567X; 1573-8744
• DOI: 10.1007/s10928-018-9571-3

Cardiovascular disease remains a significant global health burden, and development of cardiovascular drugs in the current regulatory environment often demands large and expensive cardiovascular outcome trials. Thus, the use of quantitative pharmacometric approaches which can help enable early Go/No Go decision making, ensure appropriate dose selection, and increase the likelihood of successful clinical trials, have become increasingly important to help reduce the risk of failed cardiovascular outcomes studies. In addition, cardiovascular safety is an important consideration for many drug development programs, whether or not the drug is designed to treat cardiovascular disease; modeling and simulation approaches also have utility in assessing risk in this area. Herein, examples of modeling and simulation applied at various stages of drug development, spanning from the discovery stage through late-stage clinical development, for cardiovascular programs are presented. Examples of how modeling approaches have been utilized in early development programs across various therapeutic areas to help inform strategies to mitigate the risk of cardiovascular-related adverse events, such as QTc prolongation and changes in blood pressure, are also presented. These examples demonstrate how more informed drug development decisions can be enabled by modeling and simulation approaches in the cardiovascular area.